Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
2.600
-0.040 (-1.52%)
At close: Aug 7, 2025, 4:00 PM
2.680
+0.080 (3.08%)
Pre-market: Aug 8, 2025, 8:48 AM EDT
Orchestra BioMed Holdings Employees
Orchestra BioMed Holdings had 70 employees as of December 31, 2024. The number of employees increased by 14 or 25.00% compared to the previous year.
Employees
70
Change (1Y)
14
Growth (1Y)
25.00%
Revenue / Employee
$41,229
Profits / Employee
-$947,371
Market Cap
140.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70 | 14 | 25.00% |
| Dec 31, 2023 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OBIO News
- 1 hour ago - Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility - GlobeNewsWire
- 3 days ago - Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings - GlobeNewsWire
- 7 days ago - Orchestra BioMed Announces Pricing of $40 Million Public Offering - GlobeNewsWire
- 7 days ago - Orchestra BioMed Announces Proposed Public Offering - GlobeNewsWire
- 7 days ago - Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewsWire
- 7 weeks ago - Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 - GlobeNewsWire
- 2 months ago - Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships - Seeking Alpha
- 3 months ago - Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - GlobeNewsWire